Encapsulation of biological material in the permiselective membrane allows to construct a system separating cells from their products, which may find biotechnological as well as biomedical applications in biological processes regulation. Application of a permiselective membrane allows avoiding an attack of the implanted microorganisms on the host. Our aim was to evaluate the performance of Bacillus subtilis encapsulated in an elaborate membrane system producing listeriolysin O, a cytolysin from Listeria monocytogenes, with chosen eukaryotic cells for future application in anticancer treatment. The system of encapsulating in membrane live Bacillus subtilis BR1-S secreting listeriolysin O was proven to exert the effective cytotoxic activity on eukaryotic cells. Interestingly, listeriolysin O showed selective cytotoxic activity on eukaryotic cells: more human leukemia Jurkat T cells were killed than human chronic lymphocytic B cells leukemia at similar conditions in vitro. This system of encapsulated B. subtilis, continuously releasing bacterial products, may affect selectively different types of cells and may have future application in local anticancer treatment.
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Encapsulation of biological material in the permiselective membrane allows to construct a system separating cells from their products, which may find biotechnological as well as biomedical applications in biological processes regulation [4, 5, 9, 11, 14, 15, 17, 19] . Application of a permiselective membrane physically separating implanted microorganisms from the host protects both the host (from the attack of the implanted microorganisms on the host) and the bacteria (from the host immunological response) [7] .
Bacillus subtilis is a model Gram-positive bacterium. This organism is widely used in industry, and several enzymes produced by B. subtilis are generally regarded as safe (GRAS). Its enormous secretion efficiency as well as the remarkable knowledge about its growth and fermentation conditions, combined with the possibility of gaining GRAS status for B. subtilis-derived proteins, makes this microorganism ideal for many biotechnological applications. The most remarkable feature of B. subtilis is its enormous secretion machinery. Consequently, this microorganism is widely used both in research and industry for efficient proteins production [10, 12, 16] . B. subtilis was the first platform for heterologous expression of listeriolysin O (LLO), a hemolysin from the pathogenic bacterium Listeria monocytogenes [2] . This experiment demonstrated the thin boundary between pathogenic and saprophytic microorganisms and how important LLO is for intracellular parasitism. This protein belongs to the family of cholesterol-dependent cytolysins (CDCs), a group of pore-forming toxins produced by related Gram-positive bacteria. The CDCs share very similar amino acid sequences and therefore it is believed that these toxins also share very similar planar structure. Their biochemical properties are nearly identical, with very few exceptions. Cholesterol dependence is not one of them, hence the name, which refers to the strict requirement of this lipid in the membrane for the toxin's pore-forming activity to take effect [1] . Although cholesterol is present in all eukaryotic cells membranes, cell susceptibility to cytolysis differs with respect to toxin and cell type. This phenomenon was described very early [18] , but still very little is known about its mechanism. It is postulated that cholesterol may affect the activity of CDC toxins directly, or/and it may also influence the following factors apparently important for membrane-toxins interaction: membrane fluidity, line tension, and the stabilization of lipid rafts in the cellular membrane [13] . L. monocytogenes cytolysin shows most of the typical CDC features, with one major exception: LLO shows maximal activity in acidic pH, whereas the remaining toxins favor neutral pH. Combined with a short half-life and reduced expression when the pathogen is already in the eukaryotic cell cytoplasm, this is a major adaptation of L. monocytogenes to the intracellular lifestyle [20] .
A polypropylene surface-modified hollow fiber was applied for encapsulation of the coated polyelectrolyte shells with B. subtilis cells. The applied membranes prevent bacterial escape from the lumen of the hollow fiber. Our aim was to evaluate the performance of B. subtilis encapsulated in membrane system in producing a biologically active substance with chosen eukariotic cells, for future application in anticancer treatment.
MATERIALS AND METHODS

HF Membrane Modification
Hollow fibers (HF) of polypropylene Q1 (Membrana, Germany), inner diameter 0.6 mm, wall thickness 0.2 mm, were used. HF were modified with the polyelectrolyte layer as follows: poly-L-lysine hydroxybromide, mol. wt. 1,500-3,000 (PLL) layer and polyethyleneimine solution (PEI) layer (both from Sigma, USA) were adsorbed to the hollow fiber membrane structure. The solution in 0.1 M NaCl of PLL or PEI was introduced into a membrane structure by its exposure to it in a pressure compartment (-0.1 MPa) at 20 o C for 5 min. After the deposition time, HF membranes were washed with PBS to remove unadsorbed polyelectrolyte. The polyelectrolytes were introduced consecutively into a membrane structure one by one: PLL at concentration 4 mg/ml and PEI at concentration 4 mg/ml to obtain four layers. The modified HF membrane surface is presented in Fig. 1 . The modified HF were filled up with bacterial suspension and closed at both ends.
Bacterial Strain
Bacillus subtilis strain BR1-S is an asporogenous derivative of strain ZB307 [21] producing lysteriolysin (LLO). Gene hly encoding LLO from L. monocytogenes strain 10403S was amplified using Taq polymerase (Qiagen) with the following primers: forward 5'-GCTCTA GAAGAGAGGGGTGGCAAACGGT-3' (XbaI site underlined) and reverse 5'-GCGGTCGACGGTACCTTTCGTGTGTGTTAAGCGGT-3' (sites for SalI and KpnI underlined). PCR was run in a Thermal Cycler (MJ Research, Inc.). Ampified 1.7 kb DNA fragment containing the hly gene was purified with a Gel-out kit (A&A Biotechnology) and subsequently digested with XbaI and SalI (Fermentas) enzymes. After treatment with a Purification Kit (A&A Biotechnology), the PCR product was cloned in vector pAG58 using T4 ligase (Fermentas) and transformed into Escherichia coli for further analysis. Recombinant clones were selected with the restriction analysis method and were sequenced for cloning verification. Plasmid pAG58-hly was isolated from E. coli and introduced into B. subtilis strain ZB307, resulting in strain BR1-S. Bacteria were grown at 37 o C with 120 rpm agitation in LB medium (Sigma, USA) or BHI (Becton-Dickinson, USA) supplemented with erythromycin (1 µg/ml) and chloramphenicol (3 µg/ml). To induce LLO production and release by the living bacteria, the HF-encapsulated bacteria were incubated in the presence of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma, USA).
Human Peripheral Blood Mononuclear Cells Preparation
The suspension of peripheral blood mononuclear cells was obtained from WBC of chronic lymphocytic B leukemia patients at 40,000 to 100,000 leukocytes/µl (B-CLL). The patient's leukemia B cells represented at least 90% of the whole leukocytes.
The blood was diluted twice with physiological saline, mixed, and layered on Accu-Prep reagent for mononuclear cells isolation at the volume ratio of 3:1, and centrifuged for 30 min at 2,000 rpm. The mononuclear cells (MNC) suspension (involving mainly lymphocytes and monocytes) was collected from interphase, and RPMI-1640 with 10% CS culture medium was added at 1:1 ratio, centrifuged for 15 min at 1,200 rpm and then suspended for culture. The MNC were initially cultured for 7 days to eliminate broken cells as well as trace erythrocytes and monocytes. Blood collection was approved by patients, and the procedure was approved on 27 February 2008 by the 
CYTOTOXICITY OF MEMBRANE-ENCAPSULATED BACTERIA 1195
Local Ethics Committee of the Medical Center of Postgraduate Education, Warsaw, Poland.
Evaluation of Encapsulated Bacteria Impact on Erythrocytes
The erythrocytes were prepared from 5-fold-diluted in PBS (v/v) sheep blood (Biomed, Poland), washing three times with PBS, pH 7.4 (1,200 rpm, 5 min, at 4 o C), and finally suspended in PBS, pH 7.4. The incubation medium consisted of 20% (vol) erythrocyte suspension in BHI/5 with addition of erythromycin (Sigma, USA) 3 µg/ml, chloramfenicol (Sigma, USA) 1 µg/ml, and 1 mM IPTG. BHI/5 is the BHI medium diluted with physiological saline at 1:4. Encapsulated in membrane system bacteria BR1-S at initial concentration of 10 8 cells/ml were placed and cultured in 0.5 ml of erythrocyte suspension (5% CO 2 , 37 o C). The erythrocyte suspension samples were cultured with encapsulated bacteria BR1-S not induced with IPTG addition as well. As a negative control, the erythrocyte suspensions were cultured with empty membranes. The erythrocyte suspension samples were collected after 24 h to evaluate erythrocyte density spectrophotomerically at 410 nm (optical density changes of the sample).
As a positive control, 0.01% sodium dodecyl sulfate (SDS) (Sigma, USA) was applied to check for total hemolysis.
Evaluation of Encapsulated Bacteria Impact on T-Lymphocytes Jurkat Cell Line
The Jurkat human leukemia T-lymphocyte cell line (American Type Culture Collection, Rockville, MD, USA) was maintained in RPMI-1640 supplemented with 10% newborn calf serum and 1% penicilin and streptomycin. Cells were passaged every third day by diluting to the concentration of about 0.5×10 6 cells/ml with addition of 3 µg/ml erythromycin and 1 mM IPTG for 24 h. The MNC suspension was cultured in RPMI-1640 supplemented with 10% newborn calf serum (Gibco, USA) with encapsulated bacteria BR1-S with/without IPTG addition. As a negative control, the MNC suspension was cultured with empty membranes. The samples were collected after 24 h to evaluate the cell viability in a flow cytometer in a cytochemical reaction with propidium iodide.
Evaluation of Bacteria Closure Tightness
After the procedures described above, the suspension of evaluated eukaryotic cells was divided into two equal volumes and cultures were continued: (i) after removal of membranes with encapsulated within bacteria BR1-S as a negative control; if the bacteria formerly escaped from the HF to the outside culture medium, they would proliferate and produce toxin still influencing cells viability; (ii) with the membranes containing encapsulated BR1-S cut in pieces for liberation of bacteria to the culture medium, as a positive control. After the next 24 h, the cell viability was assessed in a flow a cytometer in cytochemical reaction with propidium iodide.
Statistics
Mean values and standard deviations as well as significance of difference were calculated in the StatView 512 software. The values of p <0.05 were assumed as significant.
RESULTS
HF Membrane Modification
In Fig. 1 , a fragment of the polypropylene membrane with bacterial cell is presented. Differences in pore size as compared with dimensions of the bacteria may be noted. Changes in bacteria conformation would allow their passage through the membrane structure, even when the tested membrane cut-off (200 kDa) is lower than the bacteria size. However, to ensure tight closing of cells within the membrane system, membrane modification was applied. This prevented the leakage of bacterial cells from the HF within the period of observation.
Evaluation of Encapsulated Bacteria Impact on Erythrocytes in 24 h Experiment
The encapsulated B. subtilis exhibited different hemolytic activity depending on pH. The hemolysis of 32% or 48% with application of cysteine (reductive agent) was observed at pH 7.4; whereas at pH 5.6 there was 35% or 64% (with cysteine) of total hemolysis. The activity was in accordance with literature data for listeriolysin [20] . Total hemolysis (100%) was induced by 0.01% SDS.
Assessing the immobilized B. subtilis impact on erythrocytes, it was observed that the optical density of erythrocyte suspension (number of erythrocytes) declined about twice when cultured with IPTG-induced, encapsulated bacteria as compared with the non-induced BR1-S and negative control. This is suggesting that encapsulated BR1-S is able to produce and release LLO. The LLO crossing the membrane wall exhibited activity in erythrocyte culture outside the HF, resulting in hemolysis (Fig. 2) .
There was significant statistical difference between the optical density representing the erythrocyte number when cultured with encapsulated BR1-S +IPTG and encapsulated BR1-S or empty HF (p=0.007 and p=0.002, respectively). There was no statistical difference (p=0.520) between negative control (empty HF) and culture in the presence of noninduced BR1-S.
Evaluation of Encapsulated Bacteria Impact on Human Leukemia Jurkat Cells
The number of viable Jurkat cells declined when cultured for 24 h with encapsulated B. subtilis, as compared with a negative control (4.6±2.0% and 71.2±8.1% living cells, respectively). The percent was calculated for Jurkat cells gated (100%) on a FSC/SSC diagram. This suggests the effective action of bacterial toxins produced by membraneencapsulated B. subtilis cells. The ratio of percent number of viable cells cultured in the presence of encapsulated BR1-S induced with IPTG (BR1-S+IPTG) or not induced (BR1-S) to percent number of viable Jurkat cells cultured without encapsulated B. subtilis (negative control) is presented in Fig. 3 .
There was no Jurkat cells viability decline observed during subsequent 24 h culture in evaluated samples after removal of HF with encapsulated B. subtilis from the former Jurkat cell culture.
Evaluation of Encapsulated Bacteria Impact on Peripheral Blood Mononuclear Cells Obtained from B-CLL Patients
It was observed that the viability of leukemia cells declined as compared with a negative control (75.4±6.4% and 93.1±3.0% live cells, respectively) when cultured for 24 h with encapsulated bacteria. There was statistical significant difference between the MNC viability cultured with encapsulated BR1-S+IPTG and encapsulated BR1-S without IPTG or empty HF (negative control) (p=0.014 and p=0.0007, respectively). There was no statistical significant difference between negative control (empty HF) and culture in the presence of BR1-S ( p=0.302).
There was no observed MNC viability decline during subsequent 24 h culture after removal of HF-encapsulated B. subtilis from the MNC culture (data not presented). Therefore, we did not observe the result of free bacteria activity outside of the membrane. This suggests the effective action of the bacterial toxins produced by membraneencapsulated B. subtilis cells. In Fig. 4 is presented the ratio of percent number of viable cells cultured in the presence of encapsulated BR1-S induced with IPTG (BR1-S+IPTG) or not induced (BR1-S) to percent number of viable MNCs cultured without B. subtilis (negative control).
Comparision of B and T Leukemia Cells Susceptibility to LLO
We compared the cytotoxic effect of LLO produced by immobilized BR1-S cells on lymphocytes T (Jurkat cells) and B (MNCs from B-CLL patients). The percent number of living cells, after 24 h incubation with HF-encapsulated B. subtilis with removed background (spontaneous necrosis / apoptosis that could be detected in negative control with empty HF) was 81% of LLO-treated B-CLLs, which remained viable, and nearly 0% Jurkat cells, which were nearly all eliminated. However, Jurkat cells were also much more sensitive after incubation with noninduced BR1S cells; only 27% of T cells was intact, pointing out that the cells are overall less resistant to test conditions. To evaluate the differences in lymphocytes susceptibility to LLO, results should be presented as ratio of BR1S+IPTG treated eukaryotic cells to lymphocytes incubated with B. subtilis without IPTG (Fig. 5) . In this way, not only the background caused by spontaneous necrosis but also activity caused by other naturally produced B. subtilis proteins (i.e., proteases) can be removed, enabling the LLO cytotoxicity to be revealed. Results processed in such manner show that 15% of viable B-CLLs were eradicated with LLO, whereas 22% of viable Jurkat T cells were eliminated.
DISCUSSION
Some encapsulated microorganisms may carry a transfected gene of another organism, and thus become a source of valuable regulatory factors. Such factors released in strategic locations may direct or modify the biological processes in the eukaryotic organism [8] .
Encapsulated Bacillus subtilis demonstrated hemolytic as well as cytolytic activity, producing and secreting the toxin listeriolysin O (LLO), which diffuses to the culture medium and kills the eukaryotic cells: sheep erythrocytes, human T-lymphocyte cell line Jurkat cells, and peripheral blood mononuclear cells from leukemia patients. LLO production by B. subtilis BR1S strain is IPTG-dependent. Accordingly, the encapsulated not-induced B. subtilis exerted the toxic impact on Jurkat cells or MNC cells, respectively, at 21% or 14% lower as compared with B. subtilis induced with IPTG, suggesting that the induction of LLO production enhanced the toxic impact of bacteria on leukemia cells. There was statistical difference between the percent number of viable cells of both types of leukemia cultured in the presence of BR1-S or BR1-S + IPTG.
Two types of target leukemia cells were analyzed during the culture with encapsulated bacteria presence: Jurkat (human T-lymphocyte cell line) and peripheral blood mononuclear cells of patients with chronic lymphocytic B leukemia. The main cell population in the leukemia cells suspension were B cells, while T cells and NK lymphocytes were only the minor fraction. It was observed, that the viability of the Jurkat cells incubated 24 h with the HFencapsulated and IPTG-induced bacteria declined, as compared with the negative control. A similar effect of encapsulated B. subtilis BR1-S was observed with leukemia mononuclear cells. This suggests an effective activity of bacterial toxins produced by HF membraneencapsulated Bacillus subtilis BR1-S cells. Interestingly, the killing by encapsulated B. subtilis toxins of B-leukemia cells was less effective than in the experiment with Jurkat T-cells (Fig. 5) . There was observed difference in the viability of cells tested in the same conditions with IPTG as compared with a negative control (culture with empty HF). The difference was 18% and 67% for human B leukemia and Jurkat T leukemia cells, respectively, suggesting the selective activity of bacteria toxins to different leukemia cells. More research is necessary to confirm this hypothesis, since T and B cells came from different sources and Jurkat cells may be simply more sensitive to the testing conditions, as indicated by the low viability of these cells in the negative control compared with B-CLLs (Fig. 5) . Still, a more specific action of LLO towards T cells is possible, since more viable lymphocytes T than B were killed. Such a specifity is a very attractive hypothesis, since lymphocytes T are the main obstacle to succesfull intracellular proliferation of L. monocytogenes, and more mechanisms than direct cytolysis were described for LLO-dependent T cells elimination like apoptosis [3] and induced T cell unresponsiveness [6] . Results are presented as the ratio of BR1S+IPTG-treated eukaryotic cells to lymphocytes incubated with B. subtilis without IPTG compared with the negative control (cells suspension cultured with empty membranes).
In conclusion, the applied membrane system allows to avoid the release of Bacillus subtilis through the membrane wall. The system of membrane-encapsulated living Bacillus subtilis BR1-S secreting listeriolysin O proves the selective cytotoxic activity on eukaryotic cells, as more Jurkat leukemia T cells were killed than leukemia B cells under similar conditions in vitro. The system of encapsulated B. subtilis locally, continuously releasing bacterial products, may affect selectively different types of cells and may have future application in local anticancer treatment.
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